Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Free Cash Flow (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Free Cash Flow for 15 consecutive years, with -$844000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow fell 8.07% year-over-year to -$844000.0, compared with a TTM value of -$2.9 million through Sep 2025, up 75.27%, and an annual FY2024 reading of -$5.0 million, up 83.62% over the prior year.
  • Free Cash Flow was -$844000.0 for Q3 2025 at Alaunos Therapeutics, down from -$701000.0 in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$592000.0 in Q4 2024 and bottomed at -$21.0 million in Q2 2021.
  • Average Free Cash Flow over 5 years is -$6.9 million, with a median of -$7.1 million recorded in 2023.
  • The sharpest move saw Free Cash Flow crashed 53.85% in 2021, then soared 91.98% in 2024.
  • Year by year, Free Cash Flow stood at -$15.5 million in 2021, then skyrocketed by 53.21% to -$7.2 million in 2022, then dropped by 1.92% to -$7.4 million in 2023, then skyrocketed by 91.98% to -$592000.0 in 2024, then crashed by 42.57% to -$844000.0 in 2025.
  • Business Quant data shows Free Cash Flow for TCRT at -$844000.0 in Q3 2025, -$701000.0 in Q2 2025, and -$772000.0 in Q1 2025.